Kristen M. Bisanz

Chemogenomic Analysis Identifies Macbecin II as a Compound Specific for SMAD4‐Negative Colon Cancer Cells

C. Beaudry, Shilpi Arora, I. M. Gonzales, 2010, Chemical biology & drug design.

Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.

M. Hung, L. Chung, B. Spohn, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells.

C. Beaudry, Shilpi Arora, D. Azorsa, 2010, Assay and drug development technologies.

Ubiquitin-Independent Degradation of Antiapoptotic MCL-1

Daniel P. Stewart, J. Opferman, Rhonda M. Perciavalle, 2010, Molecular and Cellular Biology.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

Meredith C Henderson, J. Trent, S. Mousses, 2009, Journal of Translational Medicine.

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.

Shilpi Arora, D. Azorsa, R. Tibes, 2010, Gynecologic oncology.

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

C. Beaudry, D. Stephan, E. Reiman, 2010, BMC Genomics.

Chemogenomic Analysis Identifies Macbecin II as a Compound Specific for SMAD4‐Negative Colon Cancer Cells

C. Beaudry, Shilpi Arora, D. Azorsa, 2010, Chemical biology & drug design.